# SYH2095 for Advanced Malignant Tumors: Phase I Study

> **NCT07692776** · — · NOT_YET_RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SYH2095

## Key facts

- **NCT ID:** NCT07692776
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-07-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692776, "SYH2095 for Advanced Malignant Tumors: Phase I Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*